Regeneron CEO sees new blockbusters on horizon, shuns talk of selling
This article was originally published in Scrip
Regeneron Pharmaceuticals CEO Leonard Schleifer is fond of saying his biotech company is an “overnight success story” that took more than two decades to build.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.